TABLE 1.
Baseline characteristics (intention-to-treat population)
| Category | PHP-Mel (N = 44) |
BAC (N = 49) |
Treatment group comparison p value |
|---|---|---|---|
| Age [years; median (range)] | 55.0 (33–74) | 56.0 (31–77) | 0.9534 |
| Gender [n (%)] | 0.4797 | ||
| Male | 23 (52.3) | 22 (44.9) | |
| Female | 21 (47.7) | 27 (55.1) | |
| ECOG performance status [n (%)] | 0.0284 | ||
| 0 | 28 (63.6) | 42 (85.7) | |
| 1 | 13 (29.5) | 6 (12.2) | |
| Site of primary tumor [n (%)] | 0.8577 | ||
| Ocular | 39 (88.6) | 44 (89.8) | |
| Cutaneous | 5 (11.4) | 5 (10.2) | |
| Duration of hepatic metastasis [months; mean ± SD] | 4.6 ± 7.7 | 4.6 ± 5.5 | |
| Hepatic tumor burden [%; median (range)] | 32.5 (5–85) | 25.0 (5–90) | 0.5342 |
| Site of metastases [n (%)] | 0.9305 | ||
| Hepatic only | 27 (61.4) | 28 (57.1) | |
| Hepatic and extrahepatic | 17 (38.6) | 21 (42.9) | |
| Previous treatment for liver metastases [n (%)] | |||
| Chemotherapy/immunotherapy | 8 (18.2) | 10 (20.4) | 0.9008 |
| Regional therapya | 4 (9.1) | 3 (6.1) | 0.7038 |
PHP-Mel Percutaneous hepatic perfusion with melphalan, BAC best alternative care, ECOG Eastern Cooperative Oncology Group
a
Included chemoembolization, radioembolization, or ablation